FDA Adverse Event Malfunction Summary report: N

TRUEMETRIX

MDR report key: 6202160 · Received December 23, 2016

Report

Report Number
1000113657-2016-02081
Event Type
Malfunction
Date Received
December 23, 2016
Date of Event
November 30, 2016
Report Date
December 23, 2016
Manufacturer
TRIVIDIA HEALTH, INC.
Product Code
NBW
UDI-DI
00041220001286
PMA / PMN Number
K140100
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
TX
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). RETURNED METER EVALUATED WITH NO DEFECT FOUND. TEST STRIPS NOT RETURNED FOR EVALUATION. MOST LIKELY UNDERLYING ROOT CAUSE OF MALFUNCTION: USER HAD AN INACCURATE REFERENCE TEST STRIP UDI#:(B)(4).

Description of Event or Problem · 1

CONSUMER REPORTED COMPLAINT FOR HIGH BLOOD GLUCOSE TEST RESULTS. THE CUSTOMER IS CONCERNED WITH TESTS RESULTS FROM RESULTS OBTAINED OF 187MG/DL. THE CUSTOMER'S EXPECTED FASTING BLOOD GLUCOSE TEST RESULT RANGE IS 85 TO 98MG/DL. THE CUSTOMER FEELS WELL AND DID NOT REPORT ANY SYMPTOMS. THE PRODUCT IS STORED ACCORDING TO SPECIFICATION IN THE BEDROOM. MEDICAL ATTENTION IS NOT REPORTED AS A RESULT OF THE ACTUAL BLOOD GLUCOSE RESULTS. DURING THE CALL ON (B)(6) 2016, A BACK TO BACK BLOOD TEST WAS PERFORMED BY THE CUSTOMER FASTING AND PRODUCED TEST RESULTS OF 127 AND 115MG/DL USING TRUE METRIX METER. THE TEST STRIP LOT MANUFACTURER'S EXPIRATION DATE IS 12/31/2017 AND OPEN VIAL DATE IS 11/01/2016. THE METER MEMORY WAS REVIEWED FOR PREVIOUS TEST RESULT HISTORY (DATE / TIME NOT SET): 132MG/DL (B)(6) 2016 12:01 PM FASTING: YES; 131MG/DL (B)(6) 2016 06:45 AM FASTING: YES; 158MG/DL (B)(6) 2016 06:43 AM FASTING: YES; 187MG/DL (B)(6) 2016 06:42 AM FASTING: YES; 129MG/DL (B)(6) 2016 06:28 AM FASTING: YES. CUSTOMER CHANGED EXERCISE ROUTINE; CUSTOMER USED TO WALK TWO MILES AND NOW HE DOES NOT EXERCISE AS MUCH.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
852471 TRUEMETRIX BLOOD GLUCOSE SYSTEM NBW TRIVIDIA HEALTH, INC. TRUEMETRIX MT1874 00041220001286

Patients

Seq Age Sex Outcome Treatment
1 0 YR SECOND THERAPY